Alzamend Neuro, Inc. (ALZN): Price and Financial Metrics


Alzamend Neuro, Inc. (ALZN): $0.94

0.03 (+3.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALZN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALZN Stock Price Chart Interactive Chart >

Price chart for ALZN

ALZN Price/Volume Stats

Current price $0.94 52-week high $33.55
Prev. close $0.91 52-week low $0.80
Day low $0.92 Volume 642,900
Day high $1.02 Avg. volume 1,420,954
50-day MA $1.04 Dividend yield N/A
200-day MA $1.86 Market Cap 84.86M

Alzamend Neuro, Inc. (ALZN) Company Bio


Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.


ALZN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALZN Latest Social Stream


Loading social stream, please wait...

View Full ALZN Social Stream

Latest ALZN News From Around the Web

Below are the latest news stories about Alzamend Neuro Inc that investors may wish to consider to help them evaluate ALZN as an investment opportunity.

ALZN: Coordinated Offensive on Alzheimer’s Disease

By John Vandermosten, CFA NASDAQ:ALZN Alzheimer’s Disease (AD) is a feared diagnosis that afflicts many older individuals, particularly women and those with a genetic predisposition for the condition. AD is so frightening in large part because there have been no effective treatments approved for it, despite a dramatic need. With near six million Americans living with AD, growing to an anticipated

Yahoo | January 13, 2022

Univest Securities Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)

In a report issued on December 17, James Jang from Univest Securities maintained a Buy rating on Alzamend Neuro (ALZN – Research Report), with a price target of $15.00. The company's shares closed last Friday at $2.45, close to its 52-week low of $1.87. Jang has an average return of 4.4% when recommending Alzamend Neuro. According to TipRanks.com, Jang is ranked #7554 out of 7739 analysts. Currently, the analyst consensus on Alzamend Neuro is a Moderate Buy with an average price target of $11.50.

Austin Angelo on TipRanks | December 20, 2021

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determine the pharmacokinetics, safety, and tolerability of AL001 and target doses for a planned Phase 2 study in Alzheimer's patients. Related Link: See Why Alzamend Neuro Stock Is Rallying On Thursday. The participants received a single dose of AL001 containing lithium equivalent to 150 mg lithium carbona

Yahoo | December 17, 2021

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

TAMPA, Fla., December 17, 2021--Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Yahoo | December 17, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 15, 2021

Read More 'ALZN' Stories Here

ALZN Price Returns

1-mo 2.16%
3-mo -18.26%
6-mo -58.59%
1-year N/A
3-year N/A
5-year N/A
YTD -50.53%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8695 seconds.